StreetInsider.com News Articles

Lobe Sciences to Present Low-Dose L-130 Clinical Data at 9th Neuropsychiatric Drug Development Summit

Mon, 14 Sep 2026 23:00:00 -0400

● Dr. Frederick D. Sancilio to present "Reimagining Psychedelic Therapeutics for Daily Outpatient Use: Advancing Low-Dose Psilocin Beyond the Hallucinogenic Paradigm" on Wednesday, September 16

● Presentation covers Phase 1a first-in-human results for Conjugated Psilocin™ (L-130), including oral bioavailability, dose consistency and the absence of hallucinogenic effects at low doses

● Lobe to exhibit throughout the summit, September 15-17, alongside senior discovery, clinical and business development leaders from major pharmaceutical companies

VANCOUVER, BC / ACCESS Newswire / September 14, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F) ("Lobe" or the "Company"), a clinical-stage biopharmaceutical company developing

Lobe Sciences to Present Low-Dose L-130 Clinical Data at 9th Neuropsychiatric Drug Development Summit

Mon, 14 Sep 2026 23:00:00 -0400

● Dr. Frederick D. Sancilio to present "Reimagining Psychedelic Therapeutics for Daily Outpatient Use: Advancing Low-Dose Psilocin Beyond the Hallucinogenic Paradigm" on Wednesday, September 16

● Presentation covers Phase 1a first-in-human results for Conjugated Psilocin™ (L-130), including oral bioavailability, dose consistency and the absence of hallucinogenic effects at low doses

● Lobe to exhibit throughout the summit, September 15-17, alongside senior discovery, clinical and business development leaders from major pharmaceutical companies

VANCOUVER, BC / ACCESS Newswire / September 14, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F) ("Lobe" or the "Company"), a clinical-stage biopharmaceutical company developing

Lobe Sciences to Present Low-Dose L-130 Clinical Data at 9th Neuropsychiatric Drug Development Summit

Mon, 14 Sep 2026 23:00:00 -0400

● Dr. Frederick D. Sancilio to present "Reimagining Psychedelic Therapeutics for Daily Outpatient Use: Advancing Low-Dose Psilocin Beyond the Hallucinogenic Paradigm" on Wednesday, September 16

● Presentation covers Phase 1a first-in-human results for Conjugated Psilocin™ (L-130), including oral bioavailability, dose consistency and the absence of hallucinogenic effects at low doses

● Lobe to exhibit throughout the summit, September 15-17, alongside senior discovery, clinical and business development leaders from major pharmaceutical companies

VANCOUVER, BC / ACCESS Newswire / September 14, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F) ("Lobe" or the "Company"), a clinical-stage biopharmaceutical company developing

Lobe Sciences to Present Low-Dose L-130 Clinical Data at 9th Neuropsychiatric Drug Development Summit

Mon, 14 Sep 2026 23:00:00 -0400

● Dr. Frederick D. Sancilio to present "Reimagining Psychedelic Therapeutics for Daily Outpatient Use: Advancing Low-Dose Psilocin Beyond the Hallucinogenic Paradigm" on Wednesday, September 16

● Presentation covers Phase 1a first-in-human results for Conjugated Psilocin™ (L-130), including oral bioavailability, dose consistency and the absence of hallucinogenic effects at low doses

● Lobe to exhibit throughout the summit, September 15-17, alongside senior discovery, clinical and business development leaders from major pharmaceutical companies

VANCOUVER, BC / ACCESS Newswire / September 14, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F) ("Lobe" or the "Company"), a clinical-stage biopharmaceutical company developing

Lobe Sciences to Attend the ArcStone-Kingswood Growth Summit 2026 in Toronto

Mon, 14 Sep 2026 08:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - September 14, 2026) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) (FSE: LOBE.F) ("Lobe" or the "Company") is pleased to announce its participation in the upcoming 3^rd Annual ArcStone-Kingswood Growth Summit in Toronto, taking place on September 16, 2026, at the Sheraton Center Toronto Hotel. Dr. David Kideckel, Ph.D., MBA, Chief Financial Officer of Lobe Sciences, will participate as a Featured Company and will hold one-on-one meetings with interested investors and capital markets professionals.

"This is a valuable opportunity to introduce Lobe Sciences to Canadian and U.S. investors. We are advancing innovative therapies for neurological and

Lobe Sciences to Attend the ArcStone-Kingswood Growth Summit 2026 in Toronto

Mon, 14 Sep 2026 08:00:00 -0400

"This is a valuable opportunity to introduce Lobe Sciences to Canadian and U.S. investors. We are advancing innovative therapies for neurological and

Lobe Sciences to Attend the ArcStone-Kingswood Growth Summit 2026 in Toronto

Mon, 14 Sep 2026 08:00:00 -0400

"This is a valuable opportunity to introduce Lobe Sciences to Canadian and U.S. investors. We are advancing innovative therapies for neurological and

Lobe Sciences to Attend the ArcStone-Kingswood Growth Summit 2026 in Toronto

Mon, 14 Sep 2026 08:00:00 -0400

"This is a valuable opportunity to introduce Lobe Sciences to Canadian and U.S. investors. We are advancing innovative therapies for neurological and

Lobe Sciences and Alera Pharma Announce Notice of Allowance for Second U.S. Patent for Conjugated Psilocin™

Mon, 18 Nov 2024 19:00:00 -0400

U.S. Patent Office issues notice of allowance for a second patent for Conjugated Psilocin™
Once issued, this patent will provide additional coverage for psilocin mucate compositions

VANCOUVER, British Columbia & STUART, Fla.--(BUSINESS WIRE)-- Lobe Sciences, Ltd. ("Lobe Sciences" or the "Company") (CSE: LOBE), (OTCQB: LOBEF) and Alera Pharma, Inc. (“Alera” or “Alera Pharma”), biopharmaceutical companies focused on developing products to treat diseases with significant unmet medical needs, today announce that a second patent allowance for Conjugated Psilocin™ has been received. The patent application is entitled “Stable Psilocin Salts, Esters, and Conjugates and Uses Thereof”. This application contains claims

Lobe Sciences and Alera Pharma Announce Notice of Allowance for Second U.S. Patent for Conjugated Psilocin™

Mon, 18 Nov 2024 19:00:00 -0400

U.S. Patent Office issues notice of allowance for a second patent for Conjugated Psilocin™
Once issued, this patent will provide additional coverage for psilocin mucate compositions

Lobe Sciences and Alera Pharma Announce Notice of Allowance for Second U.S. Patent for Conjugated Psilocin™

Mon, 18 Nov 2024 19:00:00 -0400

U.S. Patent Office issues notice of allowance for a second patent for Conjugated Psilocin™
Once issued, this patent will provide additional coverage for psilocin mucate compositions

Lobe Sciences and Alera Pharma Announce Notice of Allowance for Second U.S. Patent for Conjugated Psilocin™

Mon, 18 Nov 2024 19:00:00 -0400

U.S. Patent Office issues notice of allowance for a second patent for Conjugated Psilocin™
Once issued, this patent will provide additional coverage for psilocin mucate compositions

Lobe Sciences and Alera Pharma Announce Notice of Allowance for Second U.S. Patent for Conjugated Psilocin™

Mon, 18 Nov 2024 19:00:00 -0400

U.S. Patent Office issues notice of allowance for a second patent for Conjugated Psilocin™
Once issued, this patent will provide additional coverage for psilocin mucate compositions

Lobe Sciences and Alera Pharma Announce Notice of Allowance for Second U.S. Patent for Conjugated Psilocin™

Mon, 18 Nov 2024 19:00:00 -0400

U.S. Patent Office issues notice of allowance for a second patent for Conjugated Psilocin™
Once issued, this patent will provide additional coverage for psilocin mucate compositions

Lobe Sciences, Ltd. Announces the Appointment of Enclave Capital and Peak Asset Management to Fund Clinical Trials of Conjugated Psilocin™

Wed, 16 Oct 2024 19:36:00 -0400

VANCOUVER, British Columbia--(BUSINESS WIRE)-- Lobe Sciences Ltd ("Lobe" or the "Company") (CSE: LOBE), (OTCQB: LOBEF), a biopharmaceutical company focused on developing products to treat diseases with significant unmet medical needs is pleased to announce the appointment of Enclave Capital and Peak Asset Management (the “Bankers”) to begin the process of raising funds to advance the development of the Company’s patented innovative pharmaceutical candidate, Conjugated Psilocin™. Lobe previously announced the creation of Alera Pharma, Inc. as an operating company to develop the drug candidate.